Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-22-011442

Chief R&D Officer sold 10,912 shares at $10.95 ($119,486)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2022-02-16 Sale : show line 1 in the form −10,912 $10.95 $119,486 274,122 D
Open-market sales · 10,912 sh · avg $10.95 · $119,486
Loading xslF345X03/doc4.xml…